159 related articles for article (PubMed ID: 31578317)
21. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
22. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
[TBL] [Abstract][Full Text] [Related]
23. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
25. Association of Leukemia Target Genes
Li J; Zhang W; Liu W; Rong J; Chen Y; Gu W; Zhang W
Cancer Genomics Proteomics; 2019; 16(5):333-344. PubMed ID: 31467227
[TBL] [Abstract][Full Text] [Related]
26. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
[TBL] [Abstract][Full Text] [Related]
27. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
28. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
29. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
Jain P; Verstovsek S; Wang W; Loghavi S; Torres HA; Estrov Z; Patel KP; Pemmaraju N
Leuk Lymphoma; 2016 Aug; 57(8):1969-73. PubMed ID: 26700872
[No Abstract] [Full Text] [Related]
30. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience.
Toogeh G; Ramzi M; Faranoush M; Amirizadeh N; Haghpanah S; Moghadam M; Cohan N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e21-6. PubMed ID: 26725263
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
[TBL] [Abstract][Full Text] [Related]
33. [Individualized treatment of leukemia patients by monitoring of minimal residual disease (MRD) based on WT1 assay].
Ogawa H; Sugiyama H
Rinsho Ketsueki; 1998 Feb; 39(2):107-8. PubMed ID: 9545812
[No Abstract] [Full Text] [Related]
34. Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.
Awada H; Durmaz A; Gurnari C; Kishtagari A; Zawit M; Pagliuca S; Visconte V
Blood Cells Mol Dis; 2021 May; 88():102549. PubMed ID: 33636567
[TBL] [Abstract][Full Text] [Related]
35. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
36. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
[TBL] [Abstract][Full Text] [Related]
37. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
[TBL] [Abstract][Full Text] [Related]
38. Detectable Wilms' tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution's experience.
Yamauchi T; Negoro E; Lee S; Takai M; Matsuda Y; Takagi K; Kishi S; Tai K; Hosono N; Tasaki T; Ikegaya S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Anticancer Res; 2013 Aug; 33(8):3335-40. PubMed ID: 23898100
[TBL] [Abstract][Full Text] [Related]
39. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
40. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
Kutny MA; Alonzo TA; Gamazon ER; Gerbing RB; Geraghty D; Lange B; Heerema NA; Sung L; Aplenc R; Franklin J; Raimondi SC; Hirsch BA; Konkashbaev A; Cox NJ; Onel K; Gamis AS; Meshinchi S
Leukemia; 2015 Dec; 29(12):2424-6. PubMed ID: 26126966
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
